3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
HKG: 1530
3SBio’s Subsidiary Achieves Milestone in Phase II Study for Chronic Sinusitis Treatment SSGJ-611
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
3SBio’s Thrombopoietin Meets Primary Endpoint in Phase III Trial for Chronic Liver Disease Patients
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced the successful conclusion...
NMPA Accepts 3SBio’s Filing for Anemia Treatment SSS06, Potential Game Changer for Dialysis Patients
3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that the...
3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...
3SBio Secures Exclusive Licensing Agreement for Seven Drug Candidates from Subsidiary
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed...
3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement...
3SBio Secures NMPA Approval for Pediatric Thrombopoietin Treatment of ITP
3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that it...
3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics
3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...
3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment
3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...
3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension
3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a...
3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received...
Sunshine Guojian’s SSGJ-608 Meets Phase III Efficacy Endpoints in Psoriasis Trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab
China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...
Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...
3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing
China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...
3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus
China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...
3SBio Inc. Initiates Phase III Clinical Study for Thrombopoietin in Chronic Liver Disease Patients
China-based 3SBio Inc. (HKG: 1530) has announced the enrollment of the first patient in a...
Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...